Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re‐PUVA and narrow‐band UVB

Background: Previous reports showed that serum levels of vascular endothelial growth factor (VEGF) are increased in patients with psoriasis. However, to our knowledge, no studies have evaluated the effects of PUVA, Re‐PUVA and narrow‐band UVB (NB‐UVB) treatments on serum levels of VEGF in patients with psoriasis.

[1]  J. Krejsek,et al.  Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy , 2007, Archives of Dermatological Research.

[2]  B. Perry,et al.  Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. , 2006, The Journal of investigative dermatology.

[3]  M. Detmar,et al.  Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. , 2006, The Journal of investigative dermatology.

[4]  M. Detmar,et al.  Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin‐1 , 2005, The British journal of dermatology.

[5]  Chun-lin Yan,et al.  Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro , 2004, Photodermatology, photoimmunology & photomedicine.

[6]  H. Young,et al.  Recent advances in cutaneous angiogenesis , 2002, The British journal of dermatology.

[7]  R. Consolini,et al.  Psoralen and UVA light: an in vitro investigation of multiple immunological mechanisms underlying the immunosuppression induction in allograft rejection. , 2002, Blood cells, molecules & diseases.

[8]  D. Creamer,et al.  Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. , 2002, Archives of dermatology.

[9]  C. Yeh,et al.  Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. , 2001, Molecular pharmacology.

[10]  C E Griffiths,et al.  Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis , 1999, The British journal of dermatology.

[11]  C. Bucana,et al.  Molecular regulation of UVB-induced cutaneous angiogenesis. , 1998, The Journal of investigative dermatology.

[12]  D. Creamer,et al.  Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma , 1996, The Lancet.

[13]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[14]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[15]  I. Braverman,et al.  Angiogenic properties of normal and psoriatic skin associate with epidermis, not dermis. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[16]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[17]  J. Voorhees,et al.  Psoralen plus black light inhibits epidermal DNA synthesis. , 1973, Archives of dermatology.